Related Experiment Video
Updated: Mar 11, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Overview of recent strategic advances in antiviral covalent inhibitors
Bo Wang1, Siyuan Wang1, Jiwei Zhang1
1Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, P.R. China.
Abstract:
Targeted covalent inhibitors (TCIs) have emerged as a promising antiviral modality, functioning through irreversible or reversible modification of conserved nucleophilic residues within essential viral proteins. These agents are increasingly recognized in antiviral drug discovery due to their potential to achieve enhanced target engagement and prolonged pharmacological effects when appropriately designed, thereby addressing limitations of traditional inhibitors such as rapid resistance development and suboptimal efficacy arising from insufficient binding durability. This review summarizes strategic frameworks for antiviral covalent inhibitor development, highlighting seminal and field-defining reports as well as recent advances. It provides a systematic overview of progress in high-throughput screening, mechanistic studies, and the integration of computational chemistry with artificial intelligence, thereby offering insights into the rational design and discovery of next-generation covalent antivirals.
Related Concept Videos
Subviral Agents
Retroviruses
Retrovirus Life Cycles
Drug Discovery: Overview
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Mechanisms of Retrovirus-induced Cancers

